Myelodysplastic Syndrome (MDS) Clinical Trial
— STIMULUS-MDS3Official title:
A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria
Verified date | May 2023 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to find out if the new drug sabatolimab when given in combination with azacitidine and venetoclax, is safe and has beneficial effects in participants with high or very high risk myelodysplastic syndrome (MDS) who are not suitable for treatment with intensive chemotherapy or a stem-cell transplant (HSCT).
Status | Completed |
Enrollment | 20 |
Est. completion date | May 8, 2023 |
Est. primary completion date | May 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study 2. Age = 18 years at the date of signing the informed consent form (ICF) 3. Morphologically confirmed diagnosis of myelodysplastic syndrome (MDS) based on 2016 WHO classification (Arber et al, 2016) by local investigator assessment with one of the following Prognostic Risk Categories, based on the revised International Prognostic Scoring System (IPSS-R) (Greenberg et al 2012): - Very high (> 6 points) - High (> 4.5-6 points) 4. Not immediately eligible for hematopoietic stem-cell transplantation (HSCT) or intensive chemotherapy at the time of screening due to individual clinical factors such as age, comorbidities and performance status, donor availability (de Witte et al 2017) 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 Exclusion Criteria: 1. Prior exposure to TIM-3 directed therapy or any BCL-2 inhibitor (including venetoclax) at any time 2. Prior therapy with immune check point inhibitors (e.g. anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2) or cancer vaccines is not allowed if the last dose of the drug was administered within 4 months prior to start of treatment 3. Previous first-line treatment for very high risk or high risk myelodysplastic syndromes (based on IPSS-R,Greenberg et al 2012 and Arber et al, 2016) with any antineoplastic agents, approved or investigational, including for example chemotherapy, lenalidomide and hypomethylating agents (HMAs) such as decitabine or azacitidine However, a one single cycle of HMAs treatment only started prior to enrollment is allowed. 4. Live vaccine administered within 30 days prior to start of treatment 5. Current use or use within 14 days prior to start of treatment of systemic steroid therapy (> 10 mg/day prednisone or equivalent) or any immunosuppressive therapy. Topical, inhaled, nasal, ophthalmic steroids are allowed. Replacement therapy, steroids given in the context of a transfusion, are allowed and not considered a form of systemic treatment 6. History of severe hypersensitivity reactions to any ingredient of study drug(s) (azacitidine, venetoclax or sabatolimab) or monoclonal antibodies (mAbs) and/or their excipients 7. Participants with Myelodysplastic syndrome (MDS) based on 2016 WHO classification (Arber et al, 2016) with revised International Prognostic Scoring System (IPSS-R) = 4.5 Other protocol-defined Inclusion/Exclusion may apply. |
Country | Name | City | State |
---|---|---|---|
Belgium | Novartis Investigative Site | Brasschaat | |
France | Novartis Investigative Site | Marseille | |
France | Novartis Investigative Site | Nice Cedex | |
Germany | Novartis Investigative Site | Duesseldorf | |
Germany | Novartis Investigative Site | Stuttgart | |
Greece | Novartis Investigative Site | Alexandroupolis | Evros |
Greece | Novartis Investigative Site | Patras | |
Hungary | Novartis Investigative Site | Nyiregyhaza | |
Italy | Novartis Investigative Site | Genova | GE |
Spain | Novartis Investigative Site | Barcelona | Catalunya |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
Belgium, France, Germany, Greece, Hungary, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of dose limiting toxicities (DLTs) (Safety run-in patients only) | Assessment of tolerability of MBG in combination with venetoclax and azacitidine | From Cycle 1 Day 8 to end of Cycle 2 (Cycle = 28 Days) | |
Primary | Percentage of participants (receiving 800mg sabatolimab) achieving complete remission (CR) per investigator assessment | This endpoint will assess Complete Remission (CR) Rate of participants from Cohort 2 of Part 1 and Part 2 according to Investigator assessment per modified IWG-MDS - Cheson 2006 criteria. CR is defined as follows: bone marrow blasts <=5%, hemoglobin level = 10 g/dL, platelets count = 100*10^9/L, neutrophils count = 1.0*10^9/L, absence of blasts in peripheral blood. | Throughout study completion, up to 3 years | |
Secondary | Percentage of subjects achieving a complete remission (CR) + morphologic complete remission (mCR): Safety run-in (Part 1) and Expansion (Part 2) | Assessing the durability of complete remission (CR) or morphologic complete remission (mCR) rate (defined as the proportion of participants with best overall response of either CR or mCR) | Throughout study completion, an average of 3 years | |
Secondary | Overall Response Rate (ORR) of participants who achieved hematologic improvement (HI) or better as best response | The percentage of participants achieving [CR + mCR + partial remission (PR) + hematologic improvement (HI)], per modified IWG-MDS Cheson 2006 criteria | Throughout study completion, an average of 3 years | |
Secondary | Percentage of participants who are RBC/platelets transfusion independent | Improvement in red blood cells (RBC)/platelets transfusion independence as per IWG-MDS by dose level | Continuously collected from start of treatment up to 3 years from last patient first treatment | |
Secondary | Duration of transfusion independence | Transfusion independence as per IWG-MDS by dose level | Continuously collected from start of treatment up to 3 years from last patient first treatment | |
Secondary | Peak Serum Concentration (Cmax) MBG453 | Maximal concentration of MBG453 | Continuously collected for patients during treatment with sabatolimab up to 150 days after last treatment | |
Secondary | Trough Serum Concentration (Cmin) MBG453 | Concentration of sabatolimab prior to next dosing or after end of treatment | Continuously collected for patients during treatment with sabatolimab up to 150 days after last treatment | |
Secondary | Anti-drug Antibody (ADA) prevalence at baseline and ADA incidence on-treatment by dose level | Immunogenicity of sabatolimab prior to sabatolimab exposure and during treatment | Continuously collected for patients during treatment with sabatolimab up to 150 days after last treatment | |
Secondary | Duration of complete remission (CR) | Duration of CR is defined as time from first occurrence of CR to relapse from CR, progression or death due to any cause whichever occurs first | Throughout study completion, an average of 3 years | |
Secondary | Time to complete remission(CR)/marrow complete remission (mCR) | Time to CR/mCR is defined as time from start of treatment to first occurrence of CR or mCR as per investigator assessment | Throughout study completion, an average of 3 years | |
Secondary | Duration of CR/mCR | Duration of CR/mCR is defined as time from first occurrence of CR/mCR to relapse from CR, progression or death due to any cause whichever occurs first | Throughout study completion, an average of 3 years | |
Secondary | Duration of response for participants who achieved hematologic improvement (HI) or better | The duration of response will be derived for participants treated with sabatolimab at the higher dose who achieve HI or better as per investigator assessment and is defined from the first occurrence of CR, mCR, PR or HI until relapse, progression or death due to any reason | Throughout study completion, an average of 3 years | |
Secondary | Progression-Free Survival (PFS) | Time from start of treatment to disease progression (including transformation to acute leukemia per WHO 2016 classification), relapse from CR or death due to any cause, whichever occurs first | Throughout study completion, an average of 3 years | |
Secondary | Leukemia-Free Survival (LFS) | Time from start of treatment to transformation to acute leukemia [as defined as = 20% blasts in bone marrow/ peripheral blood (per WHO 2016 classification) or diagnosis of extramedullary acute leukemia or death due to any cause, whichever occurs first] | Throughout study completion, an average of 3 years | |
Secondary | Event-Free Survival (EFS) | Time from start of treatment to lack of reaching CR within the first 6 cycles, relapse from CR or death due to any cause, whichever occurs first | Throughout study completion, an average of 3 years | |
Secondary | Overall Survival (OS) | Time from start of treatment to death due to any cause | Date of start of treatment to date of death due to any reason (for up to 3 years from last patient first treatment) | |
Secondary | Changes in fatigue (Part 2 - Expansion) | Changes in fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue for participants treated with sabatolimab at the higher dose of the expansion part only. Measurements are taken via scores from 0 (not at all) to 4 (very much). The higher the score, the better the Quality of Life. | Throughout the Expansion Phase, an average of 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02626715 -
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
|
Phase 2 | |
Recruiting |
NCT02905552 -
Myelodysplasic Syndromes and Risk Factors for Infection
|
N/A | |
Completed |
NCT01772953 -
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
|
Phase 2 | |
Suspended |
NCT01211691 -
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06294275 -
A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00533416 -
Safety of ON 01910.Na in Patients With Myelodysplasia
|
Phase 1 | |
Active, not recruiting |
NCT04401748 -
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
|
Phase 3 | |
Recruiting |
NCT04608110 -
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03613532 -
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
|
Phase 1 | |
Withdrawn |
NCT03486353 -
A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Terminated |
NCT02259348 -
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
|
Phase 2 | |
Terminated |
NCT01422486 -
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
|
Phase 2 | |
Terminated |
NCT01459159 -
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
|
Phase 2 | |
Terminated |
NCT00542828 -
Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT01685619 -
AML-MDS Novel Prognostic Tests Clinical Study
|
||
Recruiting |
NCT01861093 -
Safety Study of Cord Blood Units for Stem Cell Transplants
|
Phase 2 | |
Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT01758042 -
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
|
N/A | |
Completed |
NCT01338337 -
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
|
Phase 2 | |
Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 |